Skip to content

Nurix Therapeutics, Inc. NRIX License revenue — Revenue

Similar metrics at other companies

Rhythm Pharmaceuticals, Inc. logo
RYTMLicense revenue — Total revenues
$0+100%
Stoke Therapeutics, Inc. logo
STOKLicense — Revenue
$2.88M-60.9%
10x Genomics, Inc. logo
TXGLicense and royalty revenue — Revenue
$947K-94.4%
Aurinia Pharmaceuticals logo
AUPHLicense, collaboration and royalty revenue — Revenue
$4.14M+66.1%
Clearwater Analytics logo
CWANLicense — Revenue
$2.4M+153%
SoundHound AI, Inc. logo
SOUNLicensing — Revenue
$7.68M+101%

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s license revenue — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s license revenue — revenue?
Nurix Therapeutics, Inc. (NRIX) reported license revenue — revenue of $30M in Q4 2025.
What does license revenue — revenue mean?
This metric represents revenue generated from licensing intellectual property, technology platforms, or drug candidates to third-party partners. It reflects the company's ability to monetize its research and development pipeline through strategic collaborations and milestone payments. This revenue stream is a key indicator of the commercial validation of the company's proprietary drug discovery platform.